Abstract:Cyclic guanosine monophosphate (cGMP) is a second messenger produced by the NO-sensitive guanylyl cyclase (NO-GC). The NO-GC/cGMP pathway in platelets has been extensively studied. However, its role in regulating the biomechanical properties of platelets has not yet been addressed and remains unknown. We therefore investigated the stiffness of living platelets after treatment with the NO-GC stimulator riociguat or the NO-GC activator cinaciguat using scanning ion conductance microscopy (SICM). Stimulation of human and murine platelets with cGMP-modulating drugs decreased cellular stiffness and downregulated P-selectin, a marker for platelet activation. We also quantified changes in platelet shape using deep learning-based platelet morphometry, finding that platelets become more circular upon treatment with cGMP-modulating drugs. To test for clinical applicability of NO-GC stimulators in the context of increased thrombogenicity risk, we investigated the effect of riociguat on platelets from human immunodeficiency virus (HIV)-positive patients taking abacavir sulfate (ABC)-containing regimens. Our results corroborate a functional role of the NO-GC/cGMP pathway in platelet biomechanics, indicating that biomechanical properties such as stiffness or shape could be used as novel biomarkers in clinical research. Increased platelet activation and development of thrombosis has been linked to a dysfunctional NO-GC/cGMP signaling pathway. How this pathway affects platelet stiffness, however, has not been studied yet. For the first time, we used novel microscopy techniques to investigate stiffness and shape of platelets in human and murine blood samples treated with cGMP modifying drugs. Stiffness contains information about biomechanical properties of the cytoskeleton, and shape quantifies the spreading behavior of platelets. We showed that the NO-GC/cGMP signaling pathway affects platelet stiffness, shape, and activation in human and murine blood. HIV-positive patients are often treated with medication that may disrupt the NO-GC/cGMP signaling pathway, leading to increased cardiovascular risk. We showed that treatment with cGMP-modifying drugs altered platelet shape and aggregation in blood from HIV-negative volunteers but not from HIV-positive patients treated with medication. Our study suggests that platelet stiffness and shape can be biomarkers for estimating cardiovascular risk.

Altered nitric oxide/cGMP platelet signaling pathway in platelets from patients with acute coronary syndromes

Changes of Platelets Nitric Oxide Synthase Activity and Expression in Patients with Acute Coronary Syndromes

Enhanced Platelet NLRP3 Inflammasome Expression in Patients with Acute Coronary Syndrome and Stable Coronary Artery Disease: A Prospective Observational Study

Role of the NO-GC/cGMP signaling pathway in platelet biomechanics

Changes of Platelet Activation Markers and Platelet Ultra-Microstructure in the Patients with Acute Myocardial Infarction

Aspirin Acetylates Nitric Oxide Synthase Type 3 in Platelets Thereby Increasing Its Activity.

Septic shock down-regulates L-arginine/NOS/NO pathway of platelet and aortic intima in rats

Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina

The Role of NO/sGC/cGMP/PKG Signaling Pathway in Regulation of Platelet Function

Nitric Oxide Regulation of Myocardial O2 Consumption and HEP Metabolism.

Immature platelet fraction and immature platelet count as novel biomarkers of elevated platelet reactivity in NSTE-ACS patients receiving dual antiplatelet therapy

Attenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: role of protein kinase G nitration

Nitric Oxide: News from Stem Cells to Platelets

Indices of platelet activation and the stability of coronary artery disease

Changes of L-arginine-NO Pathway in Platelets of Microvascular Angina Patients and Reversing Effects of Intravenous L-arginine Infusion on L-Arg-NO Transport

Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production

Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention

Platelet activation and microvascular injury in patients with ST-segment elevation myocardial infarction

Inhibition of inducible nitric oxide synthase attenuates platelet adhesion in subpleural arterioles caused by lung ischemia-reperfusion in rabbits.

Oxidative and adhesive responses of human neutrophils to nitrovasodilators in vitro: the role of protein kinases

Changes of Reticulated Platelets and Platelet Parameters in Acute Coronary Syndrome and Their Significance